✦ LIBER ✦

Duration of trastuzumab for HER2-positive breast cancer

✍ Scribed by Montemurro, Filippo; Aglietta, Massimo

Book ID: 120932203
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 203 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70273-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant trastuzumab for HER2-positive b

Adjuvant trastuzumab for HER2-positive breast cancer

✍ James Spicer; Mark Harries; Paul Ellis 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 47 KB

Neoadjuvant trastuzumab + FEC for HER2-p

Neoadjuvant trastuzumab + FEC for HER2-positive breast cancer

📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl ⚖ 138 KB

Adjuvant Trastuzumab Therapy for HER2-Po

Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer

✍ Mohammad Jahanzeb 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 148 KB

Trastuzumab Emtansine for HER2-Positive

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

✍ Verma, Sunil; Miles, David; Gianni, Luca; Krop, Ian E.; Welslau, Manfred; Baselg 📂 Article 📅 2012 🏛 Massachusetts Medical Society 🌐 English ⚖ 365 KB

Trastuzumab for patients with HER2 posit

Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies

✍ Pinto, Ana Catarina; Ades, Felipe; de Azambuja, Evandro; Piccart-Gebhart, Martin 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 209 KB

Adjuvant Trastuzumab in HER2-Positive Br

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

✍ Slamon, Dennis; Eiermann, Wolfgang; Robert, Nicholas; Pienkowski, Tadeusz; Marti 📂 Article 📅 2011 🏛 Massachusetts Medical Society 🌐 English ⚖ 713 KB